Edition:
United Kingdom

Vectura Group PLC (VEC.L)

VEC.L on London Stock Exchange

78.00GBp
4:37pm BST
Change (% chg)

-1.10 (-1.39%)
Prev Close
79.10
Open
80.00
Day's High
80.00
Day's Low
78.00
Volume
782,497
Avg. Vol
1,042,250
52-wk High
90.15
52-wk Low
65.85

Select another date:

Sat, May 4 2019

UK's Vectura wins patent infringement case against GlaxoSmithKline in U.S

British drugmaker Vectura Group Plc said on Saturday that it won a patent infringement litigation case against GlaxoSmithKline Plc in the United States and has been awarded $89.7 million in damages for the period from August 2016 through December 2018.

UK's Vectura wins patent infringement case against GlaxoSmithKline in U.S.

May 4 British drugmaker Vectura Group Plc said on Saturday that it won a patent infringement litigation case against GlaxoSmithKline Plc in the United States and has been awarded $89.7 million in damages for the period from August 2016 through December 2018.

Vectura hopes new respiratory device will breathe life into business

Vectura Group is pinning its future on a relatively new respiratory device aimed at treating several ailments beyond asthma, as the British drugmaker looks to revive its business after the costly acquisition of rival SkyePharma in 2016.

Vectura hopes new respiratory device will breathe life into business

Vectura Group is pinning its future on a relatively new respiratory device aimed at treating several ailments beyond asthma, as the British drugmaker looks to revive its business after the costly acquisition of rival SkyePharma in 2016.

UPDATE 3-Vectura hopes new respiratory device will breathe life into business

* Forecasts 2018 adjusted core earnings above market forecasts

UK drugmaker Vectura expects 2018 earnings to top market forecasts

Jan 3 British drugmaker Vectura Group Plc on Thursday predicted that its adjusted earnings in 2018 would top market expectations, helped in part by improving profit margins.

Vectura drops severe asthma treatment after poor trial results

Britain's Vectura Group Plc will stop developing its treatment for severe uncontrolled asthma after a trial showed it failed to have a significant impact on the condition.

Vectura drops severe asthma treatment after poor trial results

Britain's Vectura Group Plc will stop developing its treatment for severe uncontrolled asthma after a trial showed it failed to have a significant impact on the condition.

UPDATE 2-Vectura drops severe asthma treatment after poor trial results

* Shares fall more than 10 percent (Adds CEO, analyst comment, share movement)

Vectura to stop developing asthma treatment after late-stage failure

Nov 26 British drugmaker Vectura Group Plc said on Monday it would stop developing its treatment for severe uncontrolled asthma after the drug-device combination failed to meet the main goal of a late-stage study.

Select another date: